Abstract
The combination of radiation and chemotherapy, based on a demonstrated preclinical rationale, has involved in the last decades the use of cytotoxic agents as radiosensitizers. Classic chemotherapeutic agents, such as 5-fluouracil and cisplatin, and more recently gemcitabine and taxanes, have been employed in different sequences with radiation therapy, even though the optimal combinations and scheduling are still in evolution. During recent years, due to the highly improved molecular understanding of intrinsic radioresistance and the profiling of cellular response to irradiation, a big effort exists in basic and translational research to identify novel treatment modalities combining radiation therapy with molecules that target very specific molecular pathways.
Keywords: Radiochemotherapy biological rationale, radiation sensitizers, 5-Fluouracil, Platinum, gemcitabine, taxol, epidermal growth factor inhibitors, epigenetic gene expression modulators
Current Drug Therapy
Title: The Association of Chemotherapy and Radiotherapy: Biological Rationale
Volume: 5 Issue: 3
Author(s): Donatella Tirindelli Danesi
Affiliation:
Keywords: Radiochemotherapy biological rationale, radiation sensitizers, 5-Fluouracil, Platinum, gemcitabine, taxol, epidermal growth factor inhibitors, epigenetic gene expression modulators
Abstract: The combination of radiation and chemotherapy, based on a demonstrated preclinical rationale, has involved in the last decades the use of cytotoxic agents as radiosensitizers. Classic chemotherapeutic agents, such as 5-fluouracil and cisplatin, and more recently gemcitabine and taxanes, have been employed in different sequences with radiation therapy, even though the optimal combinations and scheduling are still in evolution. During recent years, due to the highly improved molecular understanding of intrinsic radioresistance and the profiling of cellular response to irradiation, a big effort exists in basic and translational research to identify novel treatment modalities combining radiation therapy with molecules that target very specific molecular pathways.
Export Options
About this article
Cite this article as:
Tirindelli Danesi Donatella, The Association of Chemotherapy and Radiotherapy: Biological Rationale, Current Drug Therapy 2010; 5(3) . https://dx.doi.org/10.2174/157488510791561101
DOI https://dx.doi.org/10.2174/157488510791561101 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Meet Our Editorial Board Member
Current Medicinal Chemistry Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research TRP Channels and Pain
Current Pharmaceutical Design PDE-5 Inhibitors for BPH-Associated LUTS
Current Drug Targets Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Chromatin Structure and Epigenetics of Tumour Cells: A Review
Cardiovascular & Hematological Disorders-Drug Targets Identification and Characterization of New Proteins in Podocyte Dysfunction of Membranous Nephropathy by Proteomic Analysis of Renal Biopsy
Current Pharmacogenomics and Personalized Medicine Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
Current Medicinal Chemistry Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Subject Index To Volume 13
Current Medicinal Chemistry Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Current Drug Safety Defining Features and Exploring Chemical Modifications to Manipulate RNAa Activity
Current Pharmaceutical Biotechnology In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens
Current Pharmaceutical Design Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer: Molecular Mechanisms of Action
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) The Prediction of Carcinogenicity from Molecular Structure
Current Computer-Aided Drug Design Microfilament Actin Remodeling as a Potential Target for Cancer Drug Development
Current Cancer Drug Targets Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer
Current Medicinal Chemistry Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy